

WEDDELL, A. G. M., (A) 460	YAMAGAMI, A., (A) 245
WELCH, T. M., (A) 113	YOSHINO, Y., (A) 118
WERTHEIN, L. J., (A) 96	YOUMANS, A. Y., (A) 468
WESTERHOF, W., (A) 460	YOUMANS, G. P., (A) 468
WHITTAKER, M., (A) 89	YOUNGCHAIYUD, U., (A) 460
WILKEY, I. S., (A) 84	YUMNAN, I. S., (A) 456, 461
WILLIAMS, R. C., JR., (A) 459	
WOLINSKY, E., (A) 470	ZGRZYBLOWSKI, A., (A) 99
WU, A. M., (A) 468	
WYATT, C. R., (A) 85	

INDEX TO SUBJECTS

Names of authors or original articles (O), editorials (E), correspondence (C), and reprinted articles (R), are distinguished by capitals. Those of abstract articles (A), obituaries (Ob), book reviews (B), news and notes (N), biographies (Bio), and photographs (P), are in ordinary type.

Acid-fast characteristics,	
comments on Dr. Chatterjee's correspondence, IJL 45/3. PARES, Y.....(C)	223
use of pyridine, for differentiating <i>M. leprae</i> from other mycobacteria, in direct microscopy. SLOSAREK, M. <i>et al.</i> (O)	154
Africa,	
Albert Schweitzer, practical mystic. Dubovsky, H..... (A)	444
leprosy in, Central, epidemiologic trends. Vinet, J..... (A)	250
—, northern Nigeria. Scarborough, H. (A)	99
<i>M. ulcerans</i> infection in Cameroon, bacteriologic study. Boisvert, H..... (A)	251
—, clinical, epidemiologic and histopathologic study. Ravisse, P..... (A)	252
Nigeria, problems of uveitis in patients. Ayanru, J. O..... (A)	450
Senegal, opinions of population regarding leprosy. Sankale, M. <i>et al.</i> (A)	445
—, traditional antileprosy treatment practices, use of plants, in the Baouar. Kerharo, J..... (A)	444
Sierra Leone, West African Secretariat of ILEP produces leprosy booklet. (N)	72
Tanzania, Leprosy Mission field survey..... (N)	72
Uganda, effect of BCG against <i>M. ulcerans</i> , controlled trial. Smith, P. G. <i>et al.</i> (A)	252
Agricola, Ernani,	
obituary. Arnold, H. L., Jr. (Ob)	434
ALERT,	
publishes three leprosy teaching booklets..... (N)	440
Twelfth Annual General Meeting. Niskanen, O. (N)	229
Amyloidosis,	
in Papua New Guinea, study of amyloid fibril protein AA. Anders, R. F. <i>et al.</i> (A)	84
of the iris. Ratnakar, K. S. and Mohan, M. (A)	88
renal, nephrotic syndrome complicating ENL. Wahal, P. K. <i>et al.</i> (A)	460
Antibody,	
against BCG antigen 60, in mycobacterial infection. Harboe, M. <i>et al.</i> (A)	445
antigenic specificity of, by indirect immunofluorescence. Abe, M. and Yoshino, Y. (A)	118

circulating auto-, against thyroid and nuclear components, thyroid function evaluation in leprosy. Yumnam, I. S. <i>et al</i> (A)	461
hepatitis B, hepatitis B antigen, and subtypes in leprosy. Sher, R. <i>et al</i> (A)	240
response, in rabbits, to immunization with <i>M. leprae</i> . Harboe, M. <i>et al</i> (A)	466
—, <i>in vitro</i> , enhancement of, by adherent cells from <i>M. lepraemurium</i> -infected mice. Watson, S. R. <i>et al</i> (A)	248
stability of antimycobacterial precipitation patterns, during lepromatous leprosy treatment. BJØRVATN, B. <i>et al</i> (O)	144
to collagen, in leprosy patients. McAdam, K. P. W. J. <i>et al</i> (A)	240
Antigen(s),	
BCG 60, antibodies against in mycobacterial infection. Harboe, M. <i>et al</i> (A)	455
detection of, common to leprosy bacilli, inhibition of Rubino factor as test. ALMEIDA, J. O. DE..... (C)	436
hepatitis B, hepatitis B antibody, and subtypes in leprosy. Sher, R. <i>et al</i> (A)	240
histocompatibility, study of CMI and, in Iranian leprosy patients. MASSOUD, A. <i>et al</i> (O)	149
HLA, and leprosy. Mehra, N. K. <i>et al</i> (A)	457
—, incidence in leprosy. Youngchaiyud, U. <i>et al</i> (A)	460
ICRC-IN, grown from cultivable acid-fast bacilli from <i>M. leprae</i> , isolated from lepromatous nodules, study of skin reactions. Bapat, C. V. <i>et al</i> (A)	454
immunogenic competence, of killed <i>M. leprae</i> . Shepard, C. C. (A)	118
mycobacterial, of some mycobacteria, comparative studies, using two types of antisera. Kronvall, G. <i>et al</i> (A)	242
of <i>M. szulgai</i> , immunochemical analysis. Daniel, T. M. and DeMuth, R. W. ... (A)	469
protein, of mycobacteria, immunochemical and structural integrity of, during separation from armadillo liver antigens. Buchanan, T. M. (A)	119
Antigen, Australia (Au),	
isolation of, in leprosy patients. Lapin, N. N. <i>et al</i> (A)	87
Argentina,	
Jose M. Fernandez prize inaugurated, in field of leprosy..... (N)	439
Armadillo,	
and leprosy. Meyers, W. M. (A)	94
effect of vaccine on CMI of, against <i>M. leprae</i> . KIRCHHEIMER, W. F. <i>et al</i> (O)	353
experimental infection with <i>M. leprae</i> , quantitative aspects. Kirchheimer, W. F. <i>et al</i> (A)	109
female, plasma progesterone levels, during delayed implantation and gestation. Pepler, R. D. and Stone, S. C. (A)	96
—, scanning EM survey of brain ventricular system. Jacobs, J. J. and Monroe, K. D. (A)	466
feral, examination for mycobacteriosis, by Carville researchers. Kirchheimer, W. F. and Sanchez, R. M. (A)	94
fine structure of interstitial tissue of testis, nine-banded. Weaker, F. J. (A)	468
hematologic and temperature determinations, seven-banded. Cuba-Caparo, A. (A)	93
immunochemical and structural integrity of protein antigens of mycobacteria, during separation of liver antigens of. Buchanan, T. M. (A)	119
infection studies, role of hyaluronic acid suggested by, and bacilli cultivation in hyaluronic-acid based medium. SKINSNES, O. K. <i>et al</i> (O)	394
isolation of cultivable mycobacterium from tissues, infected with <i>M. leprae</i> , characterization of this strain. Nakamura, M. <i>et al</i> (A)	92
liver lesions in experimental lepromatoid leprosy of, histopathologic study. JOB, C. K. <i>et al</i> (O)	1
naturally acquired leprosy-like disease in, epizootiologic findings. Walsh, G. P. <i>et al</i> (A)	248
—, histopathologic and microbiologic studies of tissues. Binford, C. H. <i>et al</i> (A)	245
—, reactions in leprosy patients to lepromins prepared from. Meyers, W. M. <i>et al</i> (A)	247
occurrence of <i>M. leprae</i> in nature. Kirchheimer, W. F. (A)	466

preparation and characterization of submandibular glycoproteins. Wu, A. M. and Pigman, W. (A)	468
program, initiation of. STORRS, E. E. (C)	436
response of, to gonadotropins and steroids, to induce mating in captivity. D'Addamio, G. H. <i>et al</i> (A)	465
spermatogonia and cycle of seminiferous epithelium, nine-banded. Weaker, F. J. (A)	468
ultrastructure of salivary bladder. Ruby, J. R. and Allen, E. R. (A)	96
Arteries,	
peripheral arteriographic studies, in leprosy. Wahi, P. L. <i>et al</i> (A)	89
Australia,	
exorcizing the leper. Editorial..... (A)	232
leprosy in, management of. Forbes, J. A. (A)	248
—, Northern Territory. Gurd, C. H. (A)	464
B1912,	
analogue of clofazimine, studies. Morrison, N. E. and Marley, G. M. (A)	109
Bacillemia,	
hematological profile, in leprosy. Karat, A. B. A. and Rao, P. S. S. (A)	235
Bacteriology,	
study, of plantar ulcers with osteomyelitis underneath. Palande, D. D. <i>et al</i> (A)	453
BCG,	
effect against <i>M. ulcerans</i> disease, trial in Uganda. Smith, P. G. <i>et al</i> (A)	252
infected guinea pigs, lymphatic drainage in. Collins, F. M. and Auclair, L. (A)	246
pulmonary tuberculosis due to, in technician employed in BCG laboratory. Engbaek, H. C. <i>et al</i> (A)	251
treatment of lepromatous leprosy, with repeated increasing doses. Digoutte, J. P. <i>et al</i> (A)	447
Biopsy,	
review of over 13,000, work of Leprosy Study Centre, London. McDougall, A. C. (A)	444
Blood,	
hematological profile, general findings in leprosy. Karat, A. B. A. and Rao, P. S. S. (A)	235
Kell blood group, Kx antigen, and chronic granulomatous disease. Marsh, W. L. (A)	457
plasma fibrinogen levels and fibrinolytic activity, in lepromatous leprosy. Ramu, G. and Balakrishnan, S. (A)	88
Blood vessels,	
peripheral arteriographic studies, in leprosy. Wahi, P. L. <i>et al</i> (A)	89
ultrastructural changes in, of peripheral nerves in leprosy neuropathy. Boddington, J. (A)	238
Bone and joints,	
case of leprosy, from medieval burial ground, Poland. Gladkowska-Rzeczycka, J. (A)	239
forearm bone destruction, in leprosy. Skene-Smith, H. (A)	89
osteosclerosis, in leprosy. Racanelli, A. (A)	240
plantar ulcers, with osteomyelitis underneath. Palande, D. D. <i>et al</i> (A)	453
radionuclide bone scan abnormalities, in leprosy. Goergen, T. G. <i>et al</i> (A)	80
tarsal canal syndrome, pure cases and combined with leprosy or diabetes. Bourrel, P. <i>et al</i> (A)	451
Borderline leprosy (dimorphous and intermediate),	
peripheral nerves, and changes in blood vessels of patients with, and lepromatous leprosy. Boddington, J. (A)	238
—, and microvascular lesions in, appearance in course of acute reaction. Carayon, A. <i>et al</i> (A)	238

Brazil,		
study of community attitudes and knowledge in relation to leprosy. Frist, T.... (A)		469
Browne, Stanley G.,		
personal..... (N)		73, 439
Bulbar palsy,		
syndrome, of leprosy, due to cranial nerve involvement and its suppression.		
Namba, M. and Kobayashi, S. (A)		120
Cancer,		
and leprosy, study in Hawaii. Kolonel, L. N. and Hirohata, T..... (A)		456
test for carcinogenicity of DDS. BERGEL, M. (C)		221
Candidiasis,		
disseminated, in previously healthy girl, implication of leukocyte candidacidal defect. Staples, P. J. <i>et al</i> (A)		253
Chaulmoogra oil,		
use as an antileprotic agent in foot pad technic. Desai, A. C.		
and Bhide, M. B. (A)		447
Chemotherapy of leprosy,		
advances in antituberculosis therapy. Freerksen, E. and Rosenfeld, M. (A)		448
DDS, added in wheat flour, as possible method of leprosy treatment.		
Naik, S. S. and Pandya, S. S. (A)		449
—, or DDS-rifampin, of lepromatous patients. Peters, J. H. <i>et al</i> (A)		115
leprosy eradication project, of Malta. Freerksen, E. and Rosenfeld, M. (A)		463
long-term effect of, among contacts of lepromatous cases. Noordeen, S. K. (A)		449
of experimental leprosy, and activity of ethionamide and prothionamide.		
Colston, M. J. <i>et al</i> (A)		112
of leprosy, from microbiological standpoint. Pattyn, S. R. (A)		450
PIGO, germicidal activity of this system, on <i>M. leprae in vitro</i> . Delville,		
J. <i>et al</i> (A)		90
—, loss of infectivity of mycobacterial and protozoal exoplasmic parasites,		
after exposure <i>in vitro</i> to. Avila, J. L. <i>et al</i> (A)		90
studies of clinical course and prognosis of leprosy during, and ENL, in		
lepromatous leprosy. Takizawa, H. (A)		82
Child,		
hepatic lesions in asymptomatic, of leprosy patients. MITTAL, M. M. <i>et al</i> (O)		42
leprosy surveys in schools, assessment as method of case detection, in urban		
endemic area. Ganapati, R. <i>et al</i> (A)		464
Chimpanzee,		
spontaneous leprosy-like disease in. Conham, K. J. and Leininger, J. R. (A)		466
Cholesterol,		
a factor which is required for growth of mycobacteria, from leprosy tissues.		
KATO, L. (O)		133
and lecithin media, mycobacterial cultivation in, from lepromas of <i>M.</i>		
<i>lepraemurium</i> -infected rats. KATO, L. <i>et al</i> (O)		376
Cholinesterase,		
serum variants, in African leprosy patients. Whittaker, M. <i>et al</i> (A)		89
Clofazimine (B663),		
and eosinophilic enteritis. Mason, G. H. <i>et al</i> (A)		235
limitations of, in leprosy reactions. Sehgal, V. N. <i>et al</i> (A)		237
pigmentation. PETTIT, J. H. S. (C)		227
—, reply. SAKURAI, I..... (C)		228
studies, with analog B1912. Morrison, N. E. and Marley, G. M..... (A)		109
treatment of <i>Pyoderma gangrenosum</i> . Beurey, J. <i>et al</i> (A)		447
Coccidiomycosis,		
serum angiotensin-converting enzyme in leprosy and. Lieberman, J. (A)		456

Collagen,		
antibodies to, in leprosy patients. McAdam, K. P. W. J. <i>et al</i>	(A)	240
Complement,		
system, disorders of, in lipodystrophy. Ipp, M. M. <i>et al</i>	(A)	251
—, in tumor immunity, significance of elevated levels of, in tumor-bearing hosts. Nishioka, K. <i>et al</i>	(A)	100
Congresses,		
Eleventh International Leprosy Congress, information.....	(N)	74
—, Mexico City, November 13-18, 1978. BROWNE, S. G.	(E)	64
Contacts, leprosy,		
of lepromatous patients, long-term effects of chemotherapy. Noordeen, S. K.	(A)	449
Control of leprosy,		
and costs, application of an economic model for study. LECHAT, M. F. <i>et al</i>	(O)	14
and sulfone resistance. LECHAT, M. F.	(E)	65
Australia, management of leprosy. Forbes, J. A.	(A)	248
CIOMS conference on drug research and development, Geneva.		
Browne, S. G.	(N)	76
Cuba. Abreu, A. <i>et al</i>	(A)	96
First International Workshop in Asia, Jakarta. Browne, S. G.	(N)	73
leprosy eradication project of Malta. Freerksen, E. and Rosenfeld, M.	(A)	463
National Seminar on, Papua New Guinea, July 1978.....	(N)	442
research in campaign against leprosy. Freerksen, E.	(A)	444
review of technical cooperation and available funds, WHO.....	(A)	250
school survey assessment in case detection, in urban area endemic for leprosy.		
Ganapati, R. <i>et al</i>	(A)	464
Thailand, results of integration of control and provincial health services.		
Ramasoota, T. <i>et al</i>	(A)	249
Cowdry, Edmund Vincent,		
obituary.....	(Ob)	216
Cuba,		
leprosy control program. Abreu, A. <i>et al</i>	(A)	96
Cultivation, mycobacteria,		
cell-biological study on acid-fast organisms isolated and cultivated from lep- rosy patients, behavior of organism to experimental animals. Hirata, T.	(A)	93
cholesterol, factor required for mycobacterial growth, from leprosy tissues.		
KATO, L.	(O)	133
comments on Dr. Chatterjee's correspondence, IJL 45/3. PARES, Y.	(C)	223
<i>in vitro</i> , of leprosy bacilli in hyaluronic acid-based medium, role of hyaluronic acid suggested by culture and armadillo infection studies.		
SKINSNES, O. K. <i>et al</i>	(O)	394
—, of mycobacteria, in cholesterol-lecithin media from <i>M. lepraemurium</i> - infected rats. KATO, L. <i>et al</i>	(O)	376
<i>M. leprae</i> . Olitzki, A. L.	(A)	244
—, in cell cultures. Matsuo, Y. and Utsunomiya, S.	(A)	91
—, on modified Ogawa yolk media. Mori, T.	(A)	242
—, potential sources of energy modifying the multiplication of. Olitzki, A. L.	(A)	462
—, trial, isolation of cultivable mycobacterium from armadillo tissue infected with. Nakamura, M. <i>et al</i>	(A)	92
<i>M. lepraemurium</i> , antigenic substances of, isolation and purification of		
α -antigen. Makino, M. <i>et al</i>	(A)	117
—, enriched growth of, in flask cultures. Nakamura, M.	(A)	108
—, growth in cultures of macrophages obtained from various sources.		
Yamagami, A. and Chang, Y. T.	(A)	245
—, <i>in vitro</i> , problem of obtaining macroscopic growth. Dhople, A. M. and Hanks, J. H.	(A)	108
—, study of growth factor, minimal medium. MORI, T.	(O)	125
—, under low oxygen tensions. Mori, T.	(A)	243

<i>M. lepraemurium</i> in cell-free liquid medium, 10. Factors in starting material of <i>M. lepraemurium</i> for <i>in vitro</i> and <i>in vivo</i> growth. Nakamura, M..... (A)	92
—, 11. Establishment of Nd-5 medium. Nakamura, M. (A)	92
murine leprosy bacillus, 14. Primary and secondary cultures, observations. Ogawa, T..... (A)	243
Dapsone (DDS),	
acute renal failure, due to intravascular hemolysis. Chugh, K. S. <i>et al</i> (A)	451
added in wheat flour as possible method of leprosy therapy. Maik, S. S. and Pandya, S. S..... (A)	449
blood and tissue levels, in experimental mice. Balakrishnan, S. and Desikan, K. V..... (A)	232
blood levels, and acetylation rates of sulphadimidine, in leprosy patients. Balakrishnan, S. and Ramu, G..... (A)	447
carcinogenicity of, test. BERGEL, M..... (C)	221
cause of agranulocytosis. Firkin, F. C. and Mariani, A. F. (A)	232
characteristic anti-inflammatory effects of, as antileprosy drug. Tsutsumi, S. <i>et al</i> (A)	113
characteristics of action, on <i>M. leprae</i> multiplication, in mouse. Levy, L. and Peters, J. H..... (A)	247
intake regularity, by patients attending urban treatment center. Naik, S. S. and Ganapati, R..... (A)	237
mice fed with, growth of sulfone-resistant <i>M. leprae</i> in foot pads. Hastings, R. C. (A)	242
mixed with hydnocarpus oil, use as antileprotic agent in foot pad technic. Desai, A. C. and Bhide, M. B. (A)	447
monitoring self administration, by patients. Balakrishnan, S. (A)	447
or dapsone-rifampin, effects in chemotherapy of lepromatous patients. Peters, J. H. <i>et al</i> (A)	115
resistance, in lepromatous leprosy. Barrett, D. F. (A)	83
—, in leprosy treatment. Ambrose, E. J. <i>et al</i> (A)	446
—, infectivity of. Desai, A. C. <i>et al</i> (A)	461
—, prevalence of, in Israel. Levy, L. <i>et al</i> (A)	83
treatment of lepromatous leprosy, alone, and combined with rifampicin. Gelber, R. H. <i>et al</i> (A)	233
—, comparison of low and conventional dosages of. Iyer, C. G. S. <i>et al</i> (A)	449
—, stability of individual antimycobacterial precipitation patterns. BJORVATN, B. <i>et al</i> (O)	144
use in double-blind test, and combination of sulphamoxole and trimethoprim for treatment. Almeida Neto, E. and Jorge, M. D. (A)	446
Diabetes mellitus,	
or leprosy, in combination with cases of tarsal canal syndrome. Bourrel, P. <i>et al</i> (A)	451
Diagnosis,	
and treatment of leprosy. Jacobson, R. R. and Trautmen, J. R. (A)	80
clinical similarities between Kaposi's sarcoma, and lepromatous leprosy. Jopling, W. H..... (A)	452
dermal microfilariasis, and leprosy. McDougall, A. C. and Waudby, H..... (A)	236
histopathologic, of leprosy. Mansfield, R. E. and Binford, C. H..... (A)	87
iatrogenic claw hand from biopsy. Balina, L. M. <i>et al</i> (A)	234
in ENT practice, three unusual diagnoses: leprosy and rhinoscleroma. Bonneau, G. <i>et al</i> (A)	234
lepromatous leprosy, presenting with swelling of legs. McDougall, A. C. and Archibald, G. C. (A)	236
leprosy polyneuritis, electrophysiologic signs of subclinical importance. Papy, J. J. <i>et al</i> (A)	453
neural leprosy, in metropolitan France. Schmitt, J. <i>et al</i> (A)	237
nevi in leprosy. Barr, R. J. and Herzlinger, D. C..... (A)	454
onchocerciasis and streptocerciasis, in leprosy patients. McDougall, A. C..... (A)	236

- palmar flexion creases and dermatoglyphics, in leprosy patients.
 ESWARAIAH, G. and BALI, R. S. (O) 56
 pseudosyringomyelic form of leprosy neuritis. Schmitt, J. *et al.*..... (A) 82
 review of over 13,000 biopsies, work of Leprosy Study Centre in London.
 McDougall, A. C. (A) 444
- Dihydrofolic reductase,**
 inhibitor activity, on multiplication of *M. leprae*. Gelber, R. and Levy, L. (A) 111
- Disabilities,**
 leprosy, in New Hebrides. Bravo, L. L. and Ratard, R. C. (A) 234
 —, deformities among patients, in India. Hasan, S. (A) 451
- DOPA,**
 oxidase, histochemical identification of nonculturable mycobacteria.
 Campo-Aasen, I. and Convit, J. (A) 90
 rapid test for drug resistance, in leprosy. Ambrose, E. J. *et al.*..... (A) 446
- Drug effects,**
 acute renal failure, due to intravascular hemolysis. Chugh, K. S. *et al.* (A) 451
 characteristic anti-inflammatory effects, of several antileprosy drugs.
 Tsutsumi, S. *et al.*..... (A) 113
 clofazimine, and eosinophilic enteritis. Mason, G. H. *et al.*..... (A) 235
 clofazimine pigmentation. PETTIT, J. H. S. (C) 227
 —, reply. SAKURAI, I. (C) 228
 DDS, comparison of low and conventional dosages, lepromatous treatment.
 Iyer, C. G. S. *et al.*..... (A) 449
 inhibitory effect of tuberculo-protein complex Tubercin-3, lepromatous
 leprosy. Chung, T. H. *et al.* (A) 451
 levamisole effects, on *M. leprae*, in mice. Shepard, C. C. *et al.* (A) 467
 Tetramisol, in leprosy treatment, effect on lepromin reaction. Santos, I. (A) 450
 thalidomide, non-sedative effects in man. Hanauske-Abel, H. and Gunzler, V. (A) 449
- Drug metabolism,**
 DDS, blood and tissue levels of, in experimental mice. Balakrishnan, S.
 and Desikan, K. V. (A) 232
 —, blood levels, and acetylation rates of sulphadimidine, in leprosy patients.
 Balakrishnan, S. and Ramu, G. (A) 447
 —, and DDS-rifampin, metabolic-bacteriologic relationships, use in
 chemotherapy of lepromatous patients. Peters, J. H. *et al.* (A) 115
 non-sedative effects of thalidomide, inhibition of human prolyl hydroxylase as
 biochemical denominator. Hanauske-Abel, H. and Gunzler, V. (A) 449
 rifampin, rifampin-quinone, and desacetyl-rifampin, chemical and bacterio-
 logic assays. Goucher, C. R. *et al.*..... (A) 113
 studies with clofazimine analog, B1912. Morrison, N. E. and Marley, G. M. (A) 109
- Dubois, Albert L. M.,**
 obituary. Browne, S. G. and Lechat, M. F. (Ob) 69
- Electromyography,**
 electrical stimulation, in physiotherapy of leprosy. Hamilton, J. M. (A) 251
- Electron microscopy,**
 determination of mass of *M. leprae*. Draper, P. and Misell, D. L. (A) 461
 observations, of cell division in *M. leprae*, by serial ultrathin sectioning.
 HIRATA, T. (O) 160
 —, of intracytoplasmic membranous structures in *M. leprae*, by ultrathin
 sectioning. HIRATA, T. (O) 372
 scanning, of brain ventricular system of female armadillo. Jacobs, J. J. and
 Monroe, K. D. (A) 466
 —, study of colonies of *M. lepraemurium*. OKADA, S. *et al.*..... (O) 364
 study, of histoid leprosy, reference to histogenesis. Job, C. K. *et al.*..... (A) 456
 —, possible dysfunction of melanosome transfer, in leprosy. Westerhof, W. (A) 460

England,

- Dr. S. G. Browne awarded fellowship. Browne, S. G. (N) 439
 medieval, leprosy in. (N) 72
 The Leprosy Mission budget tops two million pounds. (N) 439

Enzyme,

- blood histamine and histaminase, in leprosy patients. Rai, V. *et al* (A) 457
 serum aldolase activity, and muscle involvement in leprosy, correlation.
 El Shiemy, S. *et al* (A) 455
 serum angiotensin-converting, in leprosy and coccidiomycosis.
 Lieberman, J. (A) 456
 serum pseudocholinesterase variants, in Mexican-born patients with
 lepromatous leprosy. REA, T. H. and NG, W. G. (O) 333
 superoxide dismutase, from *M. lepraemurium*. Ichihara, K. *et al* (A) 461

Epidemiology,

- application of economic model to study of leprosy control costs.
 LECHAT, M. F. *et al* (O) 14
 association between age of onset and mortality, lepromatous leprosy.
 SMITH, D. G. and GUINTO, R. S. (O) 25
 leprosy in, Central African empire. Vinet, J. (A) 250
 —, French Polynesia, effect of changing environmental structures on course
 of endemic disease. Merlin, M. *et al* (A) 98
 —, India, rural area in Bengal. Verma, O. P. (A) 465
 —, Northern Territory, Australia. Gurd, C. H. (A) 464
 —, Tanzania, Leprosy Mission field survey. (N) 72
 —, Thailand, results of control integration into provincial health services.
 Ramasoota, T. *et al* (A) 249
 leprosy in Okinawa, third report, the islets. Saikawa, K. (A) 249
 —, fourth report, urban area. Saikawa, K. (A) 250
 leprosy in United States, 1950-1969. Feldman, R. A. and Sturdivant, M. (A) 96
 —, 1971-1973. Golden, G. S. *et al* (A) 97
 review of technical cooperation and available funds, WHO, leprosy control. (A) 250

Erythema nodosum leprosum (ENL),

- correlation of euglobulin immunoglobulin G levels with, in lepromatous
 leprosy. Reichlin, M. *et al* (A) 458
 in lepromatous leprosy, clinical observations during chemotherapy.
 Takizawa, H. (A) 82
 nephrotic syndrome complicating, case report. Wahal, P. K. *et al* (A) 460
 thalidomide, and inhibition of de novo antibody synthesis.
 Shannon, E. J. *et al* (A) 121
 —, effects on neutrophil function. Hastings, R. C. and Morales, M. J. (A) 120
 under corticosteroid therapy, use of anabolic steroid for chronic lepra
 reaction. Choudhury, S. *et al* (A) 235

Ethionamide (Eth),

- activity of, and prothionamide, in chemotherapy of experimental leprosy.
 Colston, M. J. *et al* (A) 112

Ethiopia,

- AHRI, medical researcher position available as of January 1979. (N) 440
 ALERT, publishes three leprosy teaching booklets. (N) 440
 —, Twelfth Annual General Meeting. Niskanen, O. (N) 229

Experimental leprosy,

- armadillo, and leprosy. Meyers, W. M. (A) 94
 —, examination for mycobacteriosis. Kirchheimer, W. F. and
 Sanchez, R. M. (A) 94
 —, experimental infection with *M. leprae*. Kirchheimer, W. F. *et al* (A) 109
 —, female, plasma progesterone level during delayed implantation and
 gestation. Pepler, R. D. and Stone, S. C. (A) 96
 —, initiation of program. STORRS, E. E. (C) 436
 —, lepromatoid leprosy of, liver lesions in. JOB, C. K. *et al* (A) 1

- , seven-banded, hematologic and temperature determinations. Cuba-Caparo, A. (A) 93
- , ultrastructure of salivary bladder. Ruby, J. R. and Allen, E. R. (A) 96
- armadillo and naturally acquired leprosy-like disease in, epizootiologic findings. Walsh, G. P. *et al* (A) 248
- , histopathologic and microbiologic studies of tissues. Binford, C. H. *et al*.... (A) 245
- , reactions in leprosy patients to lepromins prepared from Meyers, W. M. *et al*..... (A) 247
- chemotherapy of, and activity of ethionamide and prothionamide. Colston, M. J. *et al*..... (A) 112
- cultivation of leprosy bacilli in hyaluronic acid-based medium, role of hyaluronic acid suggested by culture and armadillo infection studies. SKINSNES, O. K. *et al* (O) 394
- development of delayed-type hypersensitivity, during *M. lepraemurium* infection, in mice. Poulter, L. W. and Lefford, M. J. (A) 467
- effect of levamisole, on *M. leprae*, in mice. Shepard, C. C. *et al*..... (A) 467
- effect of specific vaccine, on CMI of armadillos, against *M. leprae*. KIRCHHEIMER, W. F. *et al*..... (O) 353
- guinea pigs, BCG-infected, lymphatic drainage in. Collins, F. M. and Auclair, L. (A) 246
- impairment of lymphocyte mobilization, from lymphoid organs by granulomatous infection. Bullock, W. E. and Vergamini, M. S. (A) 246
- in animals, cell-biological study on acid-fast organisms isolated and cultivated from leprosy patients, and virulence of these organisms in animals. Hirata, T. (A) 93
- in experimental mycobacterial infection, evolution of suppressor cell populations in. Bullock, W. E. (A) 122
- induction of CMI to *M. lepraemurium*, in susceptible mice. Lefford, M. J. *et al* (A) 467
- M. intracellulare* serotype Davis, histopathologic reactions following inoculation of. PETERS, M. and JINDRICH, K. (O) 346
- M. leprae* multiplication, in neonatally thymectomized Lewis rats. Fieldsteel, A. H. *et al*..... (A) 110
- , studies of dihydrofolate reductase inhibitor activity. Gelber, R. and Levy, L. (A) 111
- mice, action of dapsone on multiplication of *M. leprae*. Levy, L. and Peters, J. H. (A) 247
- , airborne infection with *M. leprae*. Rees, R. J. W. and McDougall, A. C. (A) 247
- , attempts at growth of *M. leprae*. Ogawa, T. (A) 95
- , blood and tissue levels of dapsone. Balakrishnan, S. and Desikan, K. V. (A) 232
- , foot pad, transfer of leprosy bacilli from patients to, by mosquitoes. Narayanan, E. *et al*..... (A) 247
- , infected with *M. leprae* and *M. lepraemurium*, studies on serum protein and immunoglobulin levels. Navalkar, R. G. *et al* (A) 95
- , infected with *M. lepraemurium*, enhancement of antibody response *in vitro*, by adherent cells. Watson, S. R. *et al* (A) 248
- murine leprosy, induction of depressed CMI, in ICR mice. Akiyama, T. and Esashika, I. (A) 117
- , suppressor cells in. TURCOTTE R. (O) 358
- murine leprosy and lymphocyte circulation in, description of defect. Bullock, W. E., Jr. (A) 84
- nature of defect. Bullock, W. E., Jr. (A) 85
- murine leprosy bacilli, host reactions to, in subcutaneous tissue preparations in various strains of mice. Kawaguchi, Y. *et al* (A) 246
- , effects of, on spontaneous mammary tumor, in mice. Oiwa, K. (A) 101
- observations on status of leprosy research. BERGEL, M. (C) 222
- rabbits, antibody response in, to immunization with *M. leprae*. Harboe, M. *et al*..... (A) 466
- Eye(s),**
- amyloidosis of the iris. Ratnakar, K. S. and Mohan, M. (A) 88
- complications, in long-standing leprosy patients. Deva, J. P. (A) 80

504	<i>International Journal of Leprosy</i>	1978
	corneal penetration of rifampin. Feldman, M. F. and Moses, R. A..... (A)	448
	uveitis, in Nigerian patients. Ayanru, J. O. (A)	450
Feet,		
	gait abnormalities, in leprosy. Ratton, J. F. (A)	81
	idiopathic neurotrophic feet, in Blacks. Isaacson, C..... (A)	452
	perforating ulcers of, medical treatment. Louvet, M. <i>et al</i> (A)	452
Fernandez, Jose Maria Manuel,		
	prize inaugurated in honor of, Argentina..... (N)	439
Filarial infestation,		
	dermal microfilariasis, and leprosy. McDougall, A. C. and Waudby, H..... (A)	236
	onchocerciasis and streptocerciasis, in leprosy patients. McDougall, A. C..... (A)	236
	— Meyers, W. M. and Connor, D. H..... (A)	99
	reaction in leprosy, complicated by filariasis. Nigam, P. <i>et al</i> (A)	453
Follereau, Raoul,		
	obituary. Browne, S. G. (Ob)	68
Foot pad,		
	growth of sulfone-resistant <i>M. leprae</i> in mice, fed with DDS. Hastings, R. C... (A)	242
	technic, use of hydnocarpus oil as antileprotic agent in. Desai, A. C. and Bhide, M. B. (A)	447
	suppression of immunity to <i>M. lepraemurium</i> infection. Lefford, M. J. and Mackaness, G. B..... (A)	467
France,		
	International Year for Disabled Persons, 1981. Browne, S. G..... (N)	229
	neural leprosy, in metropolitan areas. Schmitt, J. <i>et al</i> (A)	237
French Polynesia,		
	epidemiology of leprosy, effect of changing environmental structures on course of endemic disease. Merlin, M. <i>et al</i> (A)	98
Gastrointestinal tract,		
	involvement in leprosy. KAUR, S. <i>et al</i> (O)	35
Genetic susceptibility,		
	serum cholinesterase variants, in African leprosy patients. Whittaker, M. <i>et al.</i> (A)	89
Genitalia,		
	hormonal changes associated with testicular atrophy, and gynecomastia, in leprosy. Morley, J. E. <i>et al</i> (A)	88
Germany,		
	International Federation of Anti-Leprosy Foundations, new name for European Federation..... (N)	73
Giant cells,		
	serum and tissue lysozyme, in leprosy. Rea, T. H. and Taylor, C. R. (A)	458
Glomerulonephritis,		
	fatal proliferative, in lepromatous leprosy. Bedi, T. R. <i>et al</i> (A)	454
Glucose-6-phosphate dehydrogenase (G6PD),		
	deficiency, acute renal failure, due to intravascular hemolysis, in India. Chugh, K. S. <i>et al</i> (A)	451
Guinea pig,		
	BCG-infected, lymphatic drainage. Collins, F. M. and Auclair, L..... (A)	246
	induction of delayed-type hypersensitivity to human <i>M. leprae</i> in. Bloom, B. R. and Mehra, V..... (A)	119
Gynecomastia,		
	and testicular atrophy, hormonal changes associated with, in leprosy. Morley, J. E. <i>et al</i> (A)	88

Hairless mice,		
use in leprosy research. Kohsaka, K. <i>et al</i>	(A)	121
Hand(s),		
claw, iatrogenic, from diagnostic biopsy. Balina, L. M. <i>et al</i>	(A)	234
palmar flexion creases, and dermatoglyphics, in leprosy patients.		
ESWARAIAH, G. and BALI, R. S.	(O)	56
patterns of movement of totally intrinsic-minus fingers. Srinivasan, H.	(A)	82
proximal reactivation of intrinsic muscles in fingers, in cubital paralysis.		
Courbil, L.-J. <i>et al</i>	(A)	80
Hansen, Gerhard Henrik Armauer,		
biography. VOGELSANG, T. M.....	(Bio)	257
Hayashi, Yoshinobu,		
obituary. Browne, S. G.	(Ob)	70
Heart,		
cardiac dysautonomia, in leprosy. KATTRI, H. N. <i>et al</i>	(O)	172
Hemoglobin,		
hematological profile, in leprosy, general findings. Karat, A. B. A. and		
Rao, P. S. S.....	(A)	235
Histoid leprosy,		
electron microscopic study of, reference to its histogenesis. Job, C. K. <i>et al</i>	(A)	456
special reference to, clinicopathologic study of 244 leprosy cases.		
Malik, R. <i>et al</i>	(A)	457
History,		
Albert Schweitzer, practical mystic of Africa. Dubovsky, H.	(A)	444
annual discourse on leprosy. Tullis, J. L.	(A)	232
biography of G. H. A. Hansen, 1841-1912. VOGELSANG, T. M.	(Bio)	257
case of leprosy, from medieval burial ground, Poland.		
Gladykowska-Rzeczycka, J.	(A)	239
effect of changing environmental structures on course of endemic disease,		
leprosy in French Polynesia. Merlin, M. <i>et al</i>	(A)	98
exorcizing the leper, Australia. Editorial.....	(A)	232
leprosy, in Florida, to 1921. Richmond, J. S.	(A)	98
—, in medieval England.....	(N)	72
—, in northern Nigeria. Scarborough, H.	(A)	99
—, in United States, 1950-1969. Feldman, R. A. and Sturdivant, M.	(A)	96
—, in United States, 1971-1973. Golden, G. S. <i>et al</i>	(A)	97
nature of Biblical leprosy, and use of medical terms in modern translation of		
Bible. Hulse, E. V.	(A)	78
review of leprosy. Monzon, H. <i>et al</i>	(A)	445
Hodgkin's disease,		
in leprosy. Gergatz, S. J. <i>et al</i>	(A)	239
Hormones,		
hormonal changes associated with testicular atrophy and gynecomastia, in		
leprosy. Morley, J. E. <i>et al</i>	(A)	88
Hyaluronic acid,		
based medium, cultivation of leprosy bacilli in, role of suggested by culture		
and armadillo infection studies. SKINSNES, O. K. <i>et al</i>	(O)	394
Hypersensitivity, delayed-type,		
development of, during <i>M. lepraemurium</i> infection in mice. Poulter, L. W.		
and Lefford, M. J.	(A)	467
induction of, to human <i>M. leprae</i> , in guinea pigs. Bloom, B. R. and		
Mehra, V.	(A)	119
ILEP,		
meeting of Medical Commission and General Assembly, Germany,		
April 1978. Browne, S. G.....	(A)	439

West African Leprosy Secretariat of, produces booklet to assist leprosy patients..... (N)	72
Immune complexes,	
circulating, in leprosy patients, detection of and discrepancy between C1q deviation and Raji cell tests. Tung, K. S. K. <i>et al</i> (A)	459
Immunity,	
cellular, significance of lymphoblastic transformation test in leprosy.	
Languillon, J. <i>et al</i> (A)	86
current immunologic concepts of leprosy. Rea, T. H. and Levan, N. E..... (A)	232
discrepancy between C1q deviation and Raji cell tests, in detecting circulating immune complexes, in leprosy patients. Tung, K. S. K. <i>et al</i> (A)	459
humoral, complement system in tumor immunity. Nishioka, K. <i>et al</i> (A)	100
immunologic aspects of leprosy. Levinsen, A. I. <i>et al</i> (A)	87
mouse infection model, of lepromatous leprosy. Collins, F. M. and Morrison, N. E. (A)	116
Immunity, cell-mediated (CMI),	
circulating T cell numbers, and mitogenic potential in leprosy, correlation with mycobacterial load. Nath, I. <i>et al</i> (A)	457
effect of specific vaccine on, of armadillos, against <i>M. leprae</i> . KIRCHHEIMER, W. F. <i>et al</i> (O)	353
generation of, to subcutaneous <i>M. lepraemurium</i> infection, and subversion by the systemic spread of infection. Poulter, L. W. and Lefford, M. J. L..... (A)	117
immunologic responses to infections. Rook, G. A. W. (A)	89
impairment of responses, by infection with <i>M. lepraemurium</i> . Bullock, W. E. <i>et al</i> (A)	465
induction of, to <i>M. leprae</i> . Patel, P. H. <i>et al</i> (A)	119
—, to <i>M. lepraemurium</i> , in susceptible mice. Lefford, M. J. <i>et al</i> (A)	467
induction of depressed, in ICR mice infected with murine leprosy bacilli. Akiyama, T. and Esashika, I. (A)	117
study of, and histocompatibility antigens, in leprosy patients, Iran. MASSOUD, A. <i>et al</i> (O)	149
suppressor cells, in experimental murine leprosy. TURCOTTE, R. (O)	358
Immunoelectrophoresis,	
crossed, antibody response in rabbits, to immunization with <i>M. leprae</i> . Harboe, M. <i>et al</i> (A)	466
—, in determining stability of antimycobacterial precipitation patterns, during lepromatous leprosy treatment. BJORVATN, B. <i>et al</i> (O)	144
in determining Australia antigen, in leprosy patients. Lapin, N. N. <i>et al</i> (A)	87
Immunofluorescence,	
indirect, antigenic specificity of. Abe, M. and Yoshino, Y. (A)	118
Immunoglobulin(s),	
amyloid fibril protein AA, in Papua New Guinean amyloidosis.	
Anders, R. F. <i>et al</i> (A)	84
correlation of euglobulin immunoglobulin G levels with ENL, in lepromatous leprosy. Reichlin, M. <i>et al</i> (A)	458
in leprosy. GUPTA, R. M. <i>et al</i> (O)	342
serum IgE levels in leprosy. Meyruey, M. <i>et al</i> (A)	88
—, Petchclai, B. <i>et al</i> (A)	88
serum proteins and, in leprosy. GUPTA, S. C. <i>et al</i> (O)	9
Immunologic defect,	
effect of specific vaccine, on CMI of armadillos against <i>M. leprae</i> .	
KIRCHHEIMER, W. F. <i>et al</i> (O)	353
in lepromatous leprosy, transfer factor as probe of. HASTINGS, R. C..... (C)	220
Ir genes and leprosy. STONER, G. L. (C)	217
Kell blood group, Kx antigen, and chronic granulomatous disease.	
Marsh, W. L. (A)	457
nude mice, use in leprosy research. Kohsaka, K. <i>et al</i> (A)	121

Immunologic suppression,		
evolution of suppressor cell populations, in experimental mycobacterial infection. Bullock, W. E. (A)		122
suppressor cells, in experimental murine leprosy. TURCOTE, R. (O)		358
to <i>M. lepraemurium</i> infection. Lefford, M. J. and Mackaness, G. B. (A)		467
Immunotherapy,		
of leprosy. Fusaro, R. M. (A)		235
India,		
acute renal failure, in patients, northern area. Chugh, K. S. <i>et al</i> (A)		451
Acworth Leprosy Hospital holds fifth "Workshop on Leprosy." (N)		230
antileprosy week celebrations. (N)		230
Community Aid Sponsorship Program (CASP) (N)		440
Dr. S. G. Browne visits. Browne, S. G. (N)		73
epidemiologic features of leprosy, in rural area in Bengal. Verma, O. P. (A)		465
Gandhi Memorial Leprosy Foundation Report, 1975-76. Peterson, L. W. (N)		441
Hind Kusht Nivaran Sangh, Annual Report 1976. (N)		441
—, leprosy seminar at Hyderabad. Mathur, S. N. (N)		73
leprosy health education project. MATTHEWS, C. M. E. and JESUDASAN, M. (O)		414
self-healing in nonlepomatous leprosy, in area of ELEP Leprosy Control Project, Dharmapuri. Ekambaram, V. and Sithambaram, M. (A)		455
survey of leprosy deformities among patients, Hyderabad City. Hasan, S. (A)		451
The Leprosy Mission's growth in north. (N)		441
Indonesia,		
First International Workshop on Leprosy Control in Asia, Jakarta.		
Browne, S. G. (N)		73
INTERNATIONAL JOURNAL OF LEPROSY,		
editorial content of, 1933-1978. SKINSNES, O. K. (E)		426
financial statement, 1977, New Jersey and London offices. (N)		471
over to you. SKINSNES, O. K. (E)		203
postal regulations and mailing of IJL. SKINSNES, O. K. (E)		426
statement of ownership, issue Number 4. (N)		—
subscription and ILA membership notice. SKINSNES, O. K. (E)		67
International Leprosy Association,		
list of officers, councillors, members, grantors, sustaining members, and special contributors, 1978. (N)		475
subscription and ILA membership notice. SKINSNES, O. K. (E)		67
Iran,		
study of CMI, and histocompatibility antigens, in leprosy patients. MASSOUD, A. <i>et al</i> (O)		149
Isoprodian,		
new drugs in leprosy treatment, combined with rifampin. Terencio de las Aguas, J. (A)		84
Israel,		
prevalence of dapsone-resistant leprosy. Levy, L. <i>et al</i> (A)		83
Italy,		
International Workshop on Leprosy in Europe, Rome, June 1978.		
Browne, S. G. (N)		442
Kaposi's sarcoma,		
and lepomatous leprosy, clinical similarities between. Jopling, W. H. (A)		452
Labusquiere, Rene,		
obituary. Lechat, M. F. and Journiac, H. (Ob)		70
Larynx,		
laryngeal involvement, in leprosy diagnosis. Bonneau, G. <i>et al</i> (A)		234

Leishmaniasis,		
cutaneous, and leprosy. Barnettson, R. StC. and Bryceson, A. D. M. (A)		454
regulation of populations of within the host, course of <i>L. donovani</i>		
infections in mice. Bradley, D. J. and Kirkley, J. (A)		465
Lepromatous leprosy,		
and dapsone resistance. Barrett, D. F. (A)		83
and Kaposi's sarcoma, clinical similarities. Jopling, W. H. (A)		452
and tuberculoid cases, comparative sensitivity to tuberculin. Carnus,		
H. <i>et al</i> (A)		85
association between age of onset and mortality in. SMITH, D. G. and		
GUINTO, R. S. (O)		25
changes in blood vessels of peripheral nerves in, and borderline-lepromatous.		
Boddingius, J. (A)		238
chemotherapy of patients, with dapsone or dapsone-rifampin. Peters, J. H.		
<i>et al</i> (A)		115
circulating blood leukocytes from, and study of phagocytosis. ROJAS-ESPI-		
NOSA, O. (O)		337
correlation of euglobulin immunoglobulin G levels with ENL in.		
Reichlin, M. <i>et al</i> (A)		458
ENL in, clinical observations during chemotherapy. Takizawa, H. (A)		82
gingiva and periodontium, in patients. Reichart, P. <i>et al</i> (A)		89
immune defect in, use of transfer factor as probe. HASTINGS, R. C. (C)		220
in Mexican-born patients, serum pseudocholinesterase variants. REA, T. H.		
and NG, W. G. (O)		333
Ir genes and leprosy. STONER, G. L. (C)		217
long-term chemoprophylaxis among contacts of. Noordeen, S. K. (A)		449
Lucio's phenomenon, an immune complex deposition syndrome in.		
Quismorio, F. P. <i>et al</i> (A)		240
mouse infection model of. Collins, F. M. and Morrison, N. E. (A)		116
nerve abscess in, discussion of pathogenesis. Choudhury, S. B. R. and		
Srinivasan, H. (A)		455
report of atypical histopathologic picture in patient. Hernandez Angulo,		
M. <i>et al</i> (A)		86
study on plasma fibrinogen levels and fibrinolytic activity. Ramu, G. and		
Balakrishnan, S. (A)		88
treatment, comparison of low and conventional dosages of DDS.		
Iyer, C. G. S. <i>et al</i> (A)		449
—, of cases with tuberculo-protein complex prepared from <i>M. tuberculosis</i> .		
Chung, T. H. <i>et al</i> (A)		451
—, stability of individual antimycobacterial precipitation patterns during.		
BJORVATN, B. <i>et al</i> (O)		144
—, with repeated increasing doses of BCG. Digoutte, J. P. <i>et al</i> (A)		447
with histoid evolution. Calas, E. <i>et al</i> (A)		454
Lepromin,		
post-lepromin scar, observations. Walter, J. <i>et al</i> (A)		241
prepared from armadillos with naturally acquired leprosy-like disease,		
reactions in leprosy patients. Meyers, W. M. <i>et al</i> (A)		247
Tetramisole in leprosy treatment, effect on lepromin reaction. Santos, I. (A)		450
Leprosy,		
and fecundity. Carrie, J. (A)		451
and leishmaniasis. Barnettson, R. StC. and Bryceson, A. D. M. (A)		454
and tuberculosis, association. Premanath, M. and Ramu, G. (A)		101
observations on status of research. BERGEL, M. (C)		222
Leprosy Mission, The,		
budget tops two million pounds in 1978. (N)		439
field survey, of Tanzania. (N)		72
growing outreach program, in northern India. (N)		441
Lesions,		
histoid, in lepromatous leprosy. Calas, E. <i>et al</i> (A)		454

lodgement, in leprosy. SKINSNES, O. K.(E)	204
Leukocyte(s),	
circulating blood, production of superoxide by, in lepromatous patients. ROJAS-ESPINOSA, O.(O)	337
function of neutrophils, and effect of thalidomide. Hastings, R. C. and Morales, M. J.(A)	120
implication of leukocyte candidacidal defect, in patient with disseminated candidiasis. Staples, P. J. <i>et al</i>(A)	253
Levamisole,	
effect of, on <i>M. leprae</i> in mice. Shepard, C. C. <i>et al</i>(A)	467
Lewis rats,	
neonatally thymectomized, multiplication of <i>M. leprae</i> . Fieldsteel, A. H. <i>et al</i>(A)	110
Lipid(s),	
tissue, in leprosy. Verma, K. C. <i>et al</i>(A)	460
Lipodystrophy,	
disorders of complement system in. Ipp, M. M. <i>et al</i>(A)	251
Literature,	
ESSENTIALS OF LEPROSY, by Pearson, J. M. H. and Wheate, H. W.; and A FOOTWEAR MANUAL FOR LEPROSY CONTROL PROGRAMMES, PARTS 1 AND 2, by Neville, J; published by ALERT.(N)	440
¿QUE PASO? AN ENGLISH-SPANISH GUIDE FOR MEDICAL PERSONNEL, by Kantrowita, M. P., Mondragon, A. and Coleman, W. L.(N)	231
Liver,	
function, in leprosy. Gharpuray, S. M. <i>et al</i>(A)	239
hepatic lesions, in asymptomatic children of leprosy patients. MITTAL, M. M. <i>et al</i>(O)	42
lesions, experimental lepromatoid leprosy of armadillo. JOB, C. K. <i>et al</i>(O)	1
Lucio leprosy,	
phenomenon, immune complex deposition syndrome, in lepromatous leprosy. Quismorio, F. P. <i>et al</i>(A)	240
Lymph node(s),	
disturbances of lymphocyte circulation and mobilization in granulomatous disorders, of lymphoid system. Bullock, W. E. <i>et al</i>(A)	85
impairment of lymphocyte mobilization, from lymphoid organs by granulomatous infection. Bullock, W. E. and Vergamini, M. S.(A)	246
lymphatic drainage, in BCG-infected guinea pigs. Collins, F. M. and Auclair, L.(A)	246
Lymphocyte(s),	
circulation, disturbances of and mobilization in granulomatous disorders, of lymphoid system. Bullock, W. E. <i>et al</i>(A)	85
circulation in experimental murine leprosy, description of defect. Bullock, W. E.(A)	84
—, nature of defect. Bullock, W. E.(A)	85
mobilization impairment of, from lymphoid organs by granulomatous infection. Bullock, W. E. and Vergamini, M. S.(A)	246
stimulation, use in comparing preparations of <i>M. leprae</i> and other mycobacteria. BJUNE, G.(O)	386
T, and B, in spectrum of leprosy. Chogle, J. B. and Khanolkar, S. R.(A)	455
—, cell circulating numbers, and mitogenic potential in leprosy, correlation with mycobacterial load. Nath, I. <i>et al</i>(A)	457
transformation test, significance as indicator of cellular immunity. Languillon, J. <i>et al</i>(A)	86
Lymphocyte transformation,	
test, in leprosy, indicator of cellular immunity. Languillon, J. <i>et al</i>(A)	86
Lysozyme,	
serum and tissue, in leprosy. Rea, T. H. and Taylor, C. R.(A)	458

Macrophage(s),		
cultures of, growth of <i>M. lepraemurium</i> in. Yamagami, A. and		
Chang, Y. T.....	(A)	245
serum and tissue lysozyme, in leprosy. Rea, T. H. and Taylor, C. R.	(A)	458
Malta,		
leprosy eradication project. Freerksen, E. and Rosenfeld, M.	(A)	463
Mexico,		
Eleventh International Leprosy Congress. BROWNE, S. G.	(E)	64
—, information.	(N)	74
Microbiology,		
and chemotherapy, of leprosy. Pattyn, S. R.	(A)	450
recent advances, in leprosy. Dharmendra.....	(A)	461
Monoacetyldapsone (MADDS),		
metabolic-bacteriologic relationships in chemotherapy of lepromatous		
leprosy, with DDS, or DDS-rifampin. Peters, J. H. <i>et al.</i>	(A)	115
Mosquitoes,		
<i>Aedes aegypti</i> , transfer of leprosy bacilli from patients to mouse foot pads		
by. Narayanan, E. <i>et al.</i>	(A)	247
Murine leprosy,		
bacilli, collected from infected tissues, for metabolic experiments.		
Matsuki, G. <i>et al.</i>	(A)	242
—, effect of, on spontaneous mammary tumor in mice. Oiwa, K.	(A)	101
—, host reactions to, in spread subcutaneous tissue preparations, of various		
strains of mice. Kawaguchi, Y. <i>et al.</i>	(A)	246
—, 14. Observations on primary and secondary cultures of <i>M. lepraemurium</i> .		
Ogawa, T.	(A)	243
EM study of colonies of <i>M. lepraemurium</i> . OKADA, S. <i>et al.</i>	(O)	364
experimental, suppressor cells in. TURCOTTE, R.	(O)	358
induction of depressed CMI, in ICR mice infected with large doses of bacilli.		
Akiyama, T. and Esashika, I.	(A)	117
leproma, cytomorphic study of <i>M. lepraemurium</i> in. Hirata, T.	(A)	91
perturbation of lymphocyte circulations in, description of defect. Bullock,		
W. E.	(A)	84
—, nature of defect. Bullock, W. E.	(A)	85
Muscle,		
electrical stimulation, in physiotherapy of leprosy. Hamilton, J. M.	(A)	251
involvement in leprosy, and correlation with serum aldolase activity.		
El Shiemy, S. <i>et al.</i>	(A)	455
Mycobacteria,		
atypical, present status of classification. Saito, H.	(A)	92
comments on Dr. Chatterjee's correspondence, IJL 45/3. PARES, Y.	(C)	223
comparison of various preparations of, and <i>M. leprae</i> , by lymphocyte		
stimulation. BJUNE, G.	(O)	386
importance of <i>sphagnum</i> bogs in ecology of. Kazda, J.	(A)	462
<i>in vitro</i> cultivation of, in cholesterol-lecithin media, from <i>M. lepraemurium</i> -		
infected rats. KATO, L. <i>et al.</i>	(O)	376
infection, antibodies against BCG antigen 60 in. Harboe, M. <i>et al.</i>	(A)	455
inhibition of Rubino factor, as a test for detection of antigens common to		
leprosy bacilli. ALMEIDA, J. O. DE.....	(C)	436
<i>M. intracellulare</i> serotype Davis, histopathologic reactions following		
inoculation of. PETERS, M. and KAZDA, J.	(O)	346
<i>M. szulgai</i> , a new pathogen. Marks, J. <i>et al.</i>	(A)	470
—, differential identification of, and other scrotochromogenic mycobacteria.		
Selva-Sutter, E. A. <i>et al.</i>	(A)	470
numerical classification of slowly growing. Tsukamura, M.	(A)	245
staining, with periodic acid-carbol-pararosanilin. Harada, K.	(A)	241
use of pyridine for differentiating, from <i>M. leprae</i> , in direct microscopy.		
SLOSAREK, M. <i>et al.</i>	(O)	154

Mycobacterial metabolism,	
experiments, studies on collection of leprosy bacilli from infected tissues.	
Matsuki, G. <i>et al</i>	(A) 242
Mycobacterium avium,	
common antigen of, in comparative studies of mycobacteria, using two types	
antisera. Kronvall, G. <i>et al</i>	(A) 242
Mycobacterium fortuitum,	
common antigen of, in comparative studies of mycobacteria, using two types	
antisera. Kronvall, G. <i>et al</i>	(A) 242
Mycobacterium intracellulare,	
serotype Davis histopathologic reactions following intracutaneous	
inoculation of. PETERS, M. and KAZDA, J.	(O) 346
Mycobacterium leprae,	
action of DDS on multiplication of, in mouse. Levy, L. and Peters, J. J.	(A) 247
airborne infection with, in mice. Rees, R. J. W. and McDougall, A. C.	(A) 247
antibody response in rabbits immunized with. Harboe, M. <i>et al</i>	(A) 466
antigenic specificity of, by indirect immunofluorescence. Abe, M. and	
Yoshino, Y.	(A) 118
armadillos, experimental infection with. Kirchheimer, W. F. <i>et al</i>	(A) 109
cholesterol, factor required for growth of mycobacteria, from leprosy tissues.	
KATO, L.	(O) 133
comments on Dr. Chatterjee's correspondence, IJL 45/3. PARES, Y.	(C) 223
common antigen of, comparative studies using two different types of antisera.	
Kronvall, G. <i>et al</i>	(A) 242
comparison of preparations of, and other mycobacteria, by lymphocyte	
stimulation. BJUNE, G.	(O) 386
cultivation of, in cell cultures. Matsuo, Y. and Utsunomiya, S.	(A) 91
—, <i>in vitro</i> , in hyaluronic acid-based medium, role of hyaluronic acid sug-	
gested by culture and armadillo infection studies. SKINSNES, O. K. <i>et al</i>	(O) 394
—, on Ogawa yolk media. Mori, T.	(A) 242
determination of mass of, by electron microscopy. Draper, P. and	
Misell, D. L.	(A) 461
effect of vaccine, on CMI of armadillos against. KIRCHHEIMER, W. F. <i>et al</i>	(O) 353
EM observations, of cell division in, by serial ultrathin sectioning. HIRATA, T.	(O) 160
EM study, occurrence of <i>M. leprae</i> intracellularly in epidermal melanocytes,	
possible dysfunction of melanosome transfer, in leprosy. Westerhof, W.	(A) 460
found in epidermal cells, by electron microscopy. OKADA, S. <i>et al</i>	(O) 30
globi, cytological studies in leprosy. COWDRY, E. V.	(R) 175
growth of, in mice. Ogawa, T.	(A) 95
histochemical identification of, DOPA-oxidase activity. Campo-Aasen, I.	
and Convit, J.	(A) 90
human, in guinea pigs, induction of delayed-type hypersensitivity to.	
Bloom, B. R. and Mehra, V.	(A) 119
in mice, effect of levamisole. Shepard, C. C. <i>et al</i>	(A) 467
<i>in vitro</i> , germicidal activity of PIGO system on. Delville, J. <i>et al</i>	(A) 90
induction of CMI to. Patel, P. J. <i>et al</i>	(A) 119
infections in mice, lack of protection afforded by ribonucleic acid prepara-	
tions from <i>M. tuberculosis</i> against. Shepard, C. C. <i>et al</i>	(A) 468
infectivity of drug-resistant cases. Desai, A. C. <i>et al</i>	(A) 461
inhibition of Rubino factor as a test, for detecting antigens common to	
leprosy bacilli. ALMEIDA, J. O. DE	(C) 436
intracytoplasmic membranous structure in, EM observations by ultrathin	
sectioning. HIRATA, T.	(O) 372
killed, immunogenic competence of. Shepard, C. C.	(A) 118
mice infected with, studies on serum protein and immunoglobulin levels.	
Navalkar, R. G. <i>et al</i>	(A) 95
multiplication of, in neonatally thymectomized Lewis rats.	
Fieldsteel, A. H. <i>et al</i>	(A) 110
—, potential sources of energy modifying the multiplication of. Olitzki, A. L.	(A) 462

—, studies of dihydrofolate reductase inhibitor activity. Gelber, R. and Levy, L. (A)	111
new method for concentration and quantitation of. Sato, N. and Fieldsteel, A. H. (A)	244
occurrence of, in nature, discovered in armadillos. Kirchheimer, W. F. (A)	466
skin reactions in patients to lepromin and ICRC-IN, an antigen from AFB from <i>M. leprae</i> , isolated from lepromatous nodules. Bapat, C. V. <i>et al</i> (A)	454
strain of AFB isolated from armadillo leproma infected with, characterization of this strain. Nakamura, M. <i>et al</i> (A)	92
sulfone resistant, growth in foot pads of mice fed DDS. Hastings, R. C. (A)	242
two methods of demonstrating, in smears. HARADA, K. and KASAI, T. (O)	167
use of pyridine, for differentiating from other mycobacteria, in direct microscopy. SŁOSAREK, M. <i>et al</i> (O)	154
viability of, outside human body. Desikan, K. V. (A)	241
—, pretreated with rifampicin. Matsuo, Y. and Utsunomiya, S. (A)	92, 462
Mycobacterium lepraemurium,	
antigenic substances of, isolation and purification of α -antigen from. Makino, M. <i>et al</i> (A)	117
common antigen of, in comparative studies of mycobacteria using two types antisera. Kronvall, G. <i>et al</i> (A)	242
cultivation, of mycobacteria, in cholesterol-lecithin media, from rat lepromas infected with. KATO, L. <i>et al</i> (O)	376
—, under low oxygen tensions. Mori, T. (A)	243
cytomorphologic study of, in murine leproma. Hirata, T. (A)	91
enriched growth of, in flask cultures. Nakamura, M. (A)	108
evolution of suppressor cell populations, in experimental mycobacterial infection. Bullock, W. E. (A)	122
exposure <i>in vitro</i> , to PIGO. Avila, J. L. <i>et al</i> (A)	90
growth of, in cultures of macrophages obtained from various sources. Yamagami, A. and Chang, Y. T. (A)	245
histochemical identification of, DOPA-oxidase activity. Campo-Aasen, I. and Convit, J. (A)	90
impairment of cell-mediated immune responses, by infection with. Bullock, W. E. <i>et al</i> (A)	465
<i>in vitro</i> , obtaining macroscopic growth. Dhople, A. M. and Hanks, J. H. (A)	108
induction of CMI to, in susceptible mice. Lefford, M. J. <i>et al</i> (A)	467
infection, and suppression of immunity to. Lefford, M. J. and Mackaness, G. B. (A)	467
infection in mice, and development of delayed-type hypersensitivity. Poulter, L. W. and Lefford, M. J. (A)	467
—, enhancement of antibody response <i>in vitro</i> , by adherent cells from. Watson, S. R. <i>et al</i> (A)	248
—, studies on serum protein and immunoglobulin levels. Navalkar, R. G. <i>et al</i> (A)	95
multiplication in cell-free liquid medium, 10. Factors in the starting material for growth <i>in vitro</i> and <i>in vivo</i> . Nakamura, M. (A)	92
—, 11. Establishment of ND-5 medium. Nakamura, M. (A)	92
observation in subcutaneous tissue, of mice, by spread tissue preparations. Kawaguchi, Y. <i>et al</i> (A)	246
study, of colonies by electron microscopy. OKADA, S. <i>et al</i> (O)	364
—, of growth factor for, minimal medium. MORI, T. (O)	125
—, on murine leprosy bacillus. 14. Observations on primary and secondary cultures of. Ogawa, T. (A)	243
subcutaneous infection, generation of CMI to, and its subversion by the systemic spread of infection. Poulter, L. W. and Lefford, M. J. L. (A)	117
superoxide dismutase from. Ichihara, K. <i>et al</i> (A)	461
Mycobacterium scrofulaceum,	
cholesterol, a factor required for growth of mycobacteria, from leprous tissues. KATO, L. (O)	133

Mycobacterium szulgai,		
a new pathogen. Marks, J. <i>et al</i>	(A)	470
—, serologic identification and report of five new cases. Schaeffer, W. B. <i>et al</i>	(A)	470
differential identification of, and other scotochromogenic mycobacteria. Selva-Sutter, E. A. <i>et al</i>	(A)	470
major antigen of and immunochemical analysis. Daniel, T. M. and DeMuth, R. W.	(A)	469
Mycobacterium tuberculosis,		
lack of protection afforded by ribonucleic acid preparations from, against <i>M. leprae</i> infections in mice. Shepard, C. C. <i>et al</i>	(A)	468
tuberculo-protein complex prepared from, use in treatment of lepromatous leprosy. Chung, T. H. <i>et al</i>	(A)	451
Mycobacterium ulcerans,		
and leprosy infection, multiple skin testing of TB patients with range of new tuberculins, comparison with infections. Shield, M. J. <i>et al</i>	(A)	458
effect of BCG against, controlled trial in Uganda. Smith, P. G. <i>et al</i>	(A)	252
infection in Cameroon, bacteriologic study. Boisvert, H.	(A)	251
—, clinical, epidemiologic and histopathologic study. Ravisse, P.	(A)	252
Nerves,		
abscesses, in lepromatous leprosy, discussion of pathogenesis. Choudhury, S. B. R. and Srinivasan, H.	(A)	455
cranial, bulbar palsy syndrome of leprosy, due to involvement and suppression of. Namba, M. and Kobayashi, S.	(A)	120
gait abnormalities, in leprosy. Ratton, J. F.	(A)	81
inflammatory tuberculoid leprosy, with neurologic complications. Saint-Andre, P. B. <i>et al</i>	(A)	237
leprous polyneuritis, electrophysiologic signs of subclinical and diagnostic importance. Papy, J. J. <i>et al</i>	(A)	453
motor and sensory conduction velocities of, in leprosy. Singh, T. <i>et al</i>	(A)	453
neural leprosy, in metropolitan France. Schmitt, J. <i>et al</i>	(A)	237
peripheral, cutaneous, disorders of. Weddell, G.	(A)	460
—, microvascular lesions in, in course of acute reaction in borderline leprosy. Carayon, A. <i>et al</i>	(A)	238
—, neuronal studies in vitiligo. Behl, P. N. and Pradhan, B. K.	(A)	251
—, ultrastructural changes in blood vessels, borderline and lepromatous. Boddington, J.	(A)	238
surgical decompression of, prevention of deformities. PANDYA, N. J.	(O)	47
tarsal canal syndrome, pure cases and combined with leprosy or diabetes. Bourrel, P. <i>et al</i>	(A)	451
teased fiber study of early lesions of, in leprosy and contacts, with electrophysiologic correlates. Shetty, V. P. <i>et al</i>	(A)	458
ulnar biopsy, resulted in iatrogenic claw hand. Balina, L. M. <i>et al</i>	(A)	234
Nervous system,		
autonomic, cardiac dysautonomia in leprosy. KHATTRI, H. N. <i>et al</i>	(O)	172
peripheral, survey of leprosy deformities among patients. Hasan, S.	(A)	451
Neuritis,		
inflammatory tuberculoid leprosy, with neurologic complications. Saint-Andre, P. B. <i>et al</i>	(A)	237
leprous, pseudosyringomyelic form of, diagnosis and treatment. Schmitt, J. <i>et al</i>	(A)	82
leprous polyneuritis, electrophysiologic signs of subclinical and diagnostic importance. Papy, J. J. <i>et al</i>	(A)	453
Neutrophils,		
function of, and effect of thalidomide. Hastings, R. C. and Morales, M. J.	(A)	120
Nevus cells,		
nevi in leprosy. Barr, R. J. and Herzlinger, D. C.	(A)	454

New Guinea, Papua,		
National Seminar on Leprosy Control, Madang, July 1978..... (N)		442
New Hebrides,		
leprosy disabilities. Bravo, L. L. and Ratard, R. C..... (A)		234
Norway,		
biography of G. H. A. Hansen, 1841-1912. VOGELSANG, T. M.....(Bio)		257
Nose,		
rhinoscleroma, diagnosed in leprosy cases. Bonneau, G. <i>et al</i> (A)		234
surgical treatment of deformities. Antia, N. H. and Pandya, N. J. (A)		450
Obituaries,		
Agricola, Ernani. Arnold, H. L., Jr..... (Ob)		434
Cowdry, Edmund V..... (Ob)		216
Dubois, Albert. Browne, S. G. and Lechat, M. F..... (Ob)		69
Follereau, Raoul. Browne, S. G..... (Ob)		68
Hayashi, Yoshinobu. Browne, S. G..... (Ob)		70
Labusquiere, Rene. Lechat, M. F. and Journiac, H. (Ob)		70
Vogelsang, T. M. Oeding, P..... (Ob)		435
Okinawa Island,		
epidemiologic study of leprosy, on islets, 3rd report. Saikawa, K. (A)		249
—, Ryukyu Island, 4th report, urban areas. Saikawa, K..... (A)		250
Oral cavity,		
gingiva and periodontium, in lepromatous leprosy. Reichart, P. <i>et al</i> (A)		89
Pakistan,		
Dr. Ruth Pfau honored. Browne, S. G..... (N)		230
Paralysis,		
electrical stimulation, in physiotherapy of leprosy. Hamilton, J. M. (A)		251
Parasitism,		
intracellular, course of <i>Leishmania donovani</i> infections in mice. Bradley, D. J. and Kirkley, J..... (A)		465
loss of infectivity of mycobacterial and protozoal exoplasmic parasites, after exposure to polyzymic cocktail PIGO. Avila, J. L. <i>et al</i> (A)		90
Pathogenesis,		
lesion lodgement in leprosy. SKINSNES, O. K.....(E)		204
nerve abscess in lepromatous leprosy. Choudhury, S. B. R. and Srinivasan, H. (A)		455
Pfau, Ruth,		
personal. Browne, S. G. (N)		230
Phagocytosis,		
in leprosy, superoxide production by leukocytes, from lepromatous patients. ROJAS-ESPINOSA, O..... (O)		337
Physiotherapy,		
use of electrical stimulation, in leprosy. Hamilton, J. M. (A)		251
Poland,		
case of leprosy, from a medieval burial ground. Gładkowska-Rzeczycka, J. (A)		239
Progress and understanding of leprosy,		
ideas concerning a vaccine against leprosy, discussion for 11th International Congress. CONVIT, J. and ULRICH, M.....(E)		61
recent advances and present trends in leprosy research. Sansarricq, H..... (A)		79
research in campaign against leprosy. Freerksen, E. (A)		444
review of leprosy. Monzon, H. <i>et al</i> (A)		445

Prothionamide,		
activity of, and ethionamide, in chemotherapy of experimental leprosy.		
Colston, M. J. <i>et al.</i>	(A)	112
Pseudocholinesterase,		
serum variants, in Mexican-born lepromatous patients. REA, T. H. and		
NG, W. G.....	(O)	333
Public health education,		
a leprosy health education project. MATTHEWS, C. M. E. and		
JESUDASAN, M.	(O)	414
family planning in relation to leprosy, venereology and dermatology.		
Prasad, K. R.....	(A)	99
problems of reincorporating exleprosy patients into society.		
CONTRERAS DUENAS, F.	(C)	225
questionnaires requesting opinions held by Senegalese about leprosy.		
Sankale, M. <i>et al.</i>	(A)	445
study of community attitudes and knowledge, in relation to leprosy, Brazil.		
Frist, T.	(A)	469
Pyoderma gangrenosum,		
treatment with clofazimine. Beurey, J. <i>et al.</i>	(A)	447
Pyridine extraction,		
use for differentiating <i>M. leprae</i> from other mycobacteria, in direct		
microscopy. SLOSAREK, M. <i>et al.</i>	(O)	154
Quantization,		
determination of mass of <i>M. leprae</i> . by EM. Draper, P. and Misell, D. L.	(A)	461
of <i>M. leprae</i> , new method for concentration and. Sato, N. and		
Fieldsteel, A. H.	(A)	244
Rabbit,		
antibody response in, to immunization with <i>M. leprae</i> . Harboe, M. <i>et al.</i>	(A)	466
Radiography,		
of hand and foot deformities, osteosclerosis in leprosy. Racanelli, A.	(A)	240
Radiolabeling,		
immunochemical and structural integrity of protein antigens, of mycobacteria,		
during separation from armadillo liver antigens. Buchanan, T. M.....	(A)	119
Reaction,		
acute, in borderline leprosy, appearance of microvascular lesions in		
peripheral nerves. Carayon, A. <i>et al.</i>	(A)	238
chronic lepra, use of anabolic steroid. Choudhury, S. <i>et al.</i>	(A)	235
clofazimine, limitations of, in treatment. Sehgal, V. N. <i>et al.</i>	(A)	237
histopathologic, following inoculation of <i>M. intracellulare</i> serotype Davis.		
PETERS, M. and KAZDA, J.....	(O)	346
in leprosy, complicated by filariasis. Nigam, P. <i>et al.</i>	(A)	453
in leprosy patients, to lepromins prepared from naturally infected armadillos.		
Meyers, W. M. <i>et al.</i>	(A)	247
of leprosy, study of urinary nitrogenous constituents. Naik, S. S. <i>et al.</i>	(A)	233
pattern of, in leprosy. Sehgal, V. N. <i>et al.</i>	(A)	237
skin, in leprosy patients, to <i>M. leprae</i> -lepromin and ICRC-IN antigen.		
Bapat, C. V. <i>et al.</i>	(A)	454
states in leprosy, and their treatment. Jolliffe, D. S.....	(A)	452
Rehabilitation,		
electrical stimulation, in physiotherapy of leprosy. Hamilton, J. M.	(A)	251
family planning in relation to leprosy. Prasad, K. R.	(A)	99
International Year for Disabled Persons, 1981. Browne, S. G.....	(N)	229
organization, Council of World Organizations Interested in Handicapped		
(CWOIH).....	(N)	77

problems of reincorporating exleprosy patients into society. CONTRERAS DUENAS, F.(C)	225
Renal disease,	
acute failure, due to intravascular hemolysis, in North India. Chugh, K. S. <i>et al</i>(A)	451
Ribonucleic acid (RNA),	
lack of protection afforded by preparations of, from <i>M. tuberculosis</i> against <i>M. leprae</i> infections in mice. Shepard, C. C. <i>et al</i>(A)	468
Rifampicin,	
and use with isoprodian, in leprosy treatment. Terencio de las Aguas, J.....(A)	84
corneal penetration of rifampin. Feldman, M. F. and Moses, R. A.....(A)	448
dapsone or dapsone-rifampin, combination therapy in lepromatous patients. Peters, J. H. <i>et al</i>(A)	115
plus dapsone, use in short-term therapy, of lepromatous leprosy. Gelber, R. H. <i>et al</i>(A)	233
resistant leprosy. Jacobson, R. R. and Hastings, R. C.(A)	233
rifampin, rifampin-quinone and desacetyl-rifampin, chemical and bacteriologic assays. Goucher, C. R. <i>et al</i>(A)	113
—, use in treating TB and leprosy. Sanders, W. E., Jr.(A)	84
treatment of leprosy, clinical trial. Ghosh, S. <i>et al</i>(A)	448
viability of <i>M. leprae</i> , pretreated with. Matsuo, Y. and Utsunomiya, S.(A)	92, 462
Schweitzer, Albert,	
biography on. Dubovsky, H.(A)	444
Serum,	
and tissue lysozyme, in leprosy. Rea, T. H. and Taylor, C. R.....(A)	458
antibodies against BCG antigen 60, in mycobacterial infection. Harboe, M. <i>et al</i>(A)	455
blood histamine and histaminase, in leprosy patients. Rai, V. <i>et al</i>(A)	457
IgE levels in leprosy. Meyruey, M. <i>et al</i>(A)	88
—, Petchchilai, B. <i>et al</i>(A)	88
immunoglobulins, in leprosy. GUPTA, R. M. <i>et al</i>(O)	342
inhibition of Rubino factor as a test, for detecting antigens common to leprosy bacilli. ALMEIDA, J. O. DE.....(C)	436
leprosy and serodiagnostic test for tuberculosis. Cruickshank, J. G. and Ellis, B. P. B.(A)	455
<i>M. szulgai</i> , a new pathogen, serologic identification and report of five cases. Schaeffer, W. B. <i>et al</i>(A)	470
proteins, and immunoglobulins, in leprosy. GUPTA, S. C. <i>et al</i>(O)	9
pseudocholinesterase variants, in Mexican-born lepromatous patients. REA, T. H. and NG, W. G.(O)	333
serum angiotensin-converting enzyme, in leprosy and coccidiomycosis. Lieberman, J.(A)	456
Sexual dysfunction,	
leprosy and fecundity. Carrie, J.(A)	451
Skin,	
<i>M. leprae</i> found in epidermal cells, by electron microscopy. OKADA, S. <i>et al</i>(O)	30
possible dysfunction of melanosome transfer, EM study in leprosy. Westerhof, W.(A)	460
Social reaction,	
enquiry into opinions held by Senegalese about leprosy. Sankale, M. <i>et al</i>(A)	445
exorcising the leper, Australia.....(A)	232
leprosy health education project, in India. MATTHEWS, C. M. E. and JESUDASAN, M.(O)	414
problems of reincorporating exleprosy patients into society. CONTRERAS DUENAS, F.(C)	225
relation between social deviation and contagious diseases. Perez Lovelle, R. and Gonzalez Perez, V.(A)	78

46, 4	<i>Index to Subjects</i>	517
	study of community attitudes and knowledge, in relation to leprosy, Brazil. Frist, T. (A)	469
Soil,	importance of <i>sphagnum</i> bogs in ecology of <i>Mycobacteria</i> . Kazda, J. (A)	462
Spain,	problems of reincorporating leprosy patients into society. CONTRERAS DUENAS, F. (C)	225
Stain(s),	mycobacteria, with periodic acid-carbol-pararosanilin, principle and practice of method. Harada, K. (A)	241
	periodic acid-methenamine silver, for mycobacteria in tissue sections. Harada, K. (A)	86
	two methods of demonstrating leprosy bacilli in smears. HARADA, K. and KASAI, T. (O)	167
Steroid(s),	anabolic, as adjuvant in treatment of chronic lepra reaction and ENL, under corticosteroid therapy. Choudhury, S. <i>et al</i> (A)	235
Sulfone-resistant leprosy,	and leprosy control. LECHAT, M. F. (E)	65
	DDS, infectivity of cases. Desai, A. C. <i>et al</i> (A)	461
	—, mice fed with, growth of sulfone-resistant <i>M. leprae</i> in foot pads. Hastings, R. C. (A)	242
	DDS resistance, in lepromatous leprosy. Barrett, D. F. (A)	83
	—, in leprosy treatment. Ambrose, E. J. <i>et al</i> (A)	446
	—, prevalence in Israel. Levy, L. <i>et al</i> (A)	83
	drug resistance to antileprosy drugs, development and prevention. Evstratova, V. A. (A)	83
	growth of <i>M. leprae</i> , in foot pads of mice fed dapsone. Hastings, R. C. (A)	242
	primary. Jacobson, R. R. and Hastings, R. C. (A)	116
	rifampin resistance. Jacobson, R. R. and Hastings, R. C. (A)	233
Surgery,	decompression of nerves, prevention of deformities. PANDYA, N. J. (O)	47
	drop-foot correction, review. Hall, G. (A)	235
	phantom limb phenomenon, in leprosy patients. Price, D. B. (A)	81
	proximal reactivation on intrinsic muscles in fingers, in cubital paralysis. Courbil, L.-J. <i>et al</i> (A)	80
	tarsal canal syndrome, reference to pure cases and combined with leprosy or diabetes. Bourrel, P. <i>et al</i> (A)	451
	treatment of nasal deformities, review. Antia, N. H. and Pandya, N. J. (A)	450
Switzerland,	conference on drug research and development, by CIOMS, Geneva. Browne, S. G. (N)	76
Syphilis,	syphilitic leontiasis. Marchand, J.-P. <i>et al</i> (A)	81
Taxonomy,	differential identification of <i>M. szulgai</i> , and other scotochromogenic mycobacteria. Selva-Sutter, E. A. <i>et al</i> (A)	470
	present status of classification of atypical mycobacteria. Saito, H. (A)	92
Temperature,	<i>in vitro</i> cultivation of leprosy bacilli in hyaluronic acid-based medium, role of, suggested by culture and armadillo infection studies. SKINSNES, O. K. <i>et al</i> (O)	394
	lesion lodgement, in leprosy. SKINSNES, O. K. (E)	204
Tests,	inhibition of Rubino factor as a test, for detecting antigens common to leprosy bacilli. ALMEIDA, J. O. DE (C)	436

leprosy and serodiagnostic test, for tuberculosis. Cruickshank, J. G. and Ellis, B. P. B. (A)	455
Thailand,	
Phuket Island, results of five years of leprosy control integration into provincial health service. Ramasoota, T. <i>et al</i> (A)	249
Thalidomide,	
effect of, on neutrophil function. Hastings, R. C. and Morales, M. J. (A)	120
inhibition of de novo antibody synthesis by. Shannon, E. J. <i>et al</i> (A)	121
inhibition of human prolyl hydroxylase, as biochemical denominator of non-sedative effects of, in man. Hanauske-Abel, H. and Gunzler, V. (A)	449
Thymectomy,	
neonatally, in Lewis rats, multiplication of <i>M. leprae</i> . Fieldsteel, A. H. <i>et al</i> (A)	110
Thyroid,	
functions in leprosy, circulating auto-antibodies against thyroid and nuclear components. Yumnam, I. S. <i>et al</i> (A)	461
—, evaluation of, and tests. Yumnam, I. S. <i>et al</i> (A)	461
—, histopathology and evaluation. Kaur, S. <i>et al</i> (A)	456
Tissue culture,	
cultivation of <i>M. leprae</i> , in cell cultures. Matsuo, Y. and Utsunomiya, S. (A)	91
growth of <i>M. lepraemurium</i> , in cultures of macrophages obtained from various sources. Yamagami, A. and Chang, Y. T. (A)	245
<i>in vitro</i> cultivation, of <i>M. leprae</i> , in hyaluronic acid-based medium, role of, suggested by culture and armadillo infections studies.	
SKINSNES, O. K. <i>et al</i> (O)	394
—, of mycobacteria, in cholesterol-lecithin media from lepromas of rats, infected with <i>M. lepraemurium</i> . KATO, L. <i>et al</i> (O)	378
leprous, cholesterol, a factor which is required for growth of mycobacteria from. KATO, L. (O)	133
Transfer factor,	
as a probe in immune defect, in lepromatous leprosy. HASTINGS, R. C. (C)	220
Ir genes and leprosy. STONER, G. L. (C)	217
Transmission,	
airborne infection with <i>M. leprae</i> , in mice. Rees, R. J. W. and McDougall, A. C. (A)	247
transfer of leprosy bacilli, from patients to mouse foot pads, by mosquitoes. Narayanan, E. <i>et al</i> (A)	247
Treatment,	
and diagnosis, of leprosy. Jacobson, R. R. and Trautman, J. R. (A)	80
BCG, lepromatous leprosy with repeated increasing doses.	
Digoutte, J. P. <i>et al</i> (A)	447
clofazimine, and eosinophilic enteritis. Mason, G. H. <i>et al</i> (A)	235
—, limitations of, in lepra reaction. Sehgal, V. N. <i>et al</i> (A)	237
clofazimine pigmentation. PETTIT, J. H. S. (C)	227
—, reply. SAKURAI, I. (C)	228
corneal penetration of rifampin. Feldman, M. F. and Moses, R. A. (A)	448
DDS, and combined with rifampicin, in short-term therapy of lepromatous leprosy. Gelber, R. H. <i>et al</i> (A)	233
—, cause of agranulocytosis. Firkin, F. C. and Mariani, A. F. (A)	232
—, comparison of low and conventional dosages, lepromatous leprosy. Iyer, C. G. S. <i>et al</i> (A)	449
—, double-blind test, use of combination of sulphamoxole and trimethoprim. Almeida Neto, E. and Jorge, M. D. (A)	446
—, intake regularity by patients, at urban treatment center. Naik, S. S. and Ganapati, R. (A)	237
—, monitoring of self-treatment by patients. Balakrishnan, S. (A)	447
—, rapid test for drug resistance. Ambrose, E. J. <i>et al</i> (A)	446
drug resistance to antileprosy drugs, development and prevention. Evstratova, V. A. (A)	83

lepromatous leprosy, and stability of individual antimycobacterial precipitation patterns. BJORVATN, B. <i>et al</i>	(O)	144
—, use of tuberculo-protein complex on cases. Chung, T. H. <i>et al</i>	(A)	451
leprosy health education project. MATTHEWS, C. M. E. and JESUDASAN, M.	(O)	414
new drugs, rifampicin and with isoprodian. Terencio de las Aguas, J.	(A)	84
of leprosy reactional states. Jolliffe, D. S.	(A)	452
perforating ulcers of feet, in leprosy. Louvet, M. <i>et al</i>	(A)	452
plantar ulcer, use of Polambakkam splint. Antony, P.	(A)	450
rifampicin, clinical trial. Ghosh, S. <i>et al</i>	(A)	448
rifampin, useful in TB and leprosy. Sanders, W. E., Jr.	(A)	84
self-healing in nonlepromatous leprosy. Ekambaram, V. and Sithambaram, M.	(A)	455
surgical, nasal deformities, review. Antia, N. H. and Pandya, N. J.	(A)	450
Tetramisole, effect on lepromin reaction. Santos, I.	(A)	450
use of anabolic steroid, for chronic lepra reaction and ENL, under corticosteroid therapy. Choudhury, S. <i>et al</i>	(A)	235
use of plants, traditional antileprosy treatment practices in the Baouar, Senegal. Kerharo, J.	(A)	444
Tuberculin,		
comparative sensitivity to, in lepromatous and tuberculoid cases. Carnus, H. <i>et al</i>	(A)	85
complement system in tumor immunity, elevated levels of complement in tumor-bearing hosts. Nishioka, K. <i>et al</i>	(A)	100
new range of, skin testing of tuberculosis patients, comparison with leprosy and <i>M. ulcerans</i> infection. Shield, M. J. <i>et al</i>	(A)	458
Tuberculoid leprosy,		
and lepromatous cases, comparative sensitivity to tuberculin in. Carnus, H. <i>et al</i>	(A)	85
clinical features. Chapman, R. S. and Forsyth, A.	(A)	79
inflammatory, with neurologic complications. Saint-Andre, P. B. <i>et al</i>	(A)	237
Tuberculosis,		
advances in therapy. Freerksen, E. and Rosenfeld, M.	(A)	448
and leprosy. Vachharajani, S. D. <i>et al</i>	(A)	459
—, association. Premanath, M. and Ramu, G.	(A)	101
chromophobic tubercle bacilli, and problem of endogenous reactivation of TB. Nyka, W.	(A)	252
multiple skin testing of patients, with range of new tuberculins, comparison with leprosy and <i>M. ulcerans</i> infections. Shield, M. J. <i>et al</i>	(A)	458
pulmonary, due to BCG, in technician employed in BCG laboratory. Engbaek, H. C. <i>et al</i>	(A)	251
serodiagnostic test for, and leprosy. Cruickshank, J. G. and Ellis, B. P. B.	(A)	455
Ulcer(s),		
perforating, of foot in leprosy, treatment. Louvet, M. <i>et al</i>	(A)	452
plantar, treatment with Polambakkam splint. Antony, P.	(A)	450
—, with osteomyelitis underneath. Palande, D. D. <i>et al</i>	(A)	453
trophic, in leprosy patients, management. Srivastava, K. P. and Kesarwani, R. C.	(A)	82
United Arab Republic,		
Cairo Second International Leprosy and Tropical Dermatology Congress, March 1978. Browne, S. G.	(N)	229
Urine,		
nitrogenous constituents, in leprosy reactions. Naik, S. S. <i>et al</i>	(A)	233
U.S.A.,		
ALM-USPHS 20th Annual International Seminar on Leprosy, to be held in Carville, April 1979.	(N)	442
Council of World Organizations Interested in the Handicapped, organization.	(N)	77

English-Spanish guide for medical personnel available, entitled, ¿QUE PASO? ... (N)	231
leprosy in, 1950-1969. Feldman, R. A. and Sturdivant, M. (A)	96
—, 1971-1973. Golden, G. S. <i>et al</i> (A)	97
—, Florida to 1921, history of. Richmond, J. S. (A)	98
—, Kansas. Liu, J. N. <i>et al</i> (A)	98
The STAR, of Carville, now has complete index available..... (N)	231
Victor Heiser Awards for Research in Leprosy available. (N)	443
U.S.-Japan Cooperative Medical Science Program,	
Twelfth Joint Leprosy Research Conference, Boston, Massachusetts, Sept. 27-29, 1977. (A)	102
Vaccination,	
lack of protection afforded by ribonucleic acid preparations from <i>M. tuber-</i> <i>culosis</i> against <i>M. leprae</i> infections in mice. Shepard, C. C. <i>et al</i> (A)	468
rabbits, antibody response in, to immunization with <i>M. leprae</i> . Harboe, M. <i>et al</i> (A)	466
Vaccine,	
against leprosy, ideas concerning, basis for discussion during 11th Int. Leprosy Congress. CONVIT, J. and ULRICH, M. (E)	61
effect of, on CMI of armadillos against <i>M. leprae</i> . KIRCHHEIMER, W. F. <i>et al</i> ... (O)	353
Viability,	
of <i>M. leprae</i> , outside human body. Desikan, K. V. (A)	241
—, pretreated with rifampicin. Matsuo, Y. and Utsunomiya, S. (A)	92, 462
Vietnam, South,	
dermatological problems, during 1970-1975, war years. Zgrzyblowski, A. and Rozen, L. (A)	99
Vitiligo,	
neuronal studies. Behl, P. N. and Pradhan, B. K. (A)	251
Vogelsang, Thomas M.,	
obituary. Oeding, P. (Ob)	435
World Health Organization (WHO),	
leprosy control, review of technical cooperation and available funds..... (A)	250